(Q45351582)

English

Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine

scientific article published on 16 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine (English)

1 reference

Europe PubMed Central

13 December 2017

vector-borne disease

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chin-Fen Yang

1

1 reference

Europe PubMed Central

13 December 2017

C Kathy Wang

2

1 reference

Europe PubMed Central

13 December 2017

Elissa Malkin

3

1 reference

Europe PubMed Central

13 December 2017

Jeanne H Schickli

4

1 reference

Europe PubMed Central

13 December 2017

Cindy Shambaugh

5

1 reference

Europe PubMed Central

13 December 2017

Fengrong Zuo

6

1 reference

Europe PubMed Central

13 December 2017

Mark S Galinski

7

1 reference

Europe PubMed Central

13 December 2017

Filip Dubovsky

8

1 reference

Europe PubMed Central

13 December 2017

Study Group

9

1 reference

Europe PubMed Central

13 December 2017

Roderick S Tang

10

1 reference

Europe PubMed Central

13 December 2017

language of work or name

0 references

publication date

16 April 2013

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

31

1 reference

Europe PubMed Central

13 December 2017

26

1 reference

Europe PubMed Central

13 December 2017

2822-2827

1 reference

Europe PubMed Central

13 December 2017

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Respiratory syncytial virus: a prioritized or neglected target?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Challenges in developing a pediatric RSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.006

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.04.006

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45351582&oldid=2075518060"